In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 10, 1998, Pages 2674-2677

  Oleksijew, Andy ^a   Meulbroek, Jon ^a   Ewing, Patty ^a   Jarvis, Ken ^a   Mitten, Mike ^a   Paige, Lenette ^a   Tovcimak, Ann ^a   Nukkula, Mike ^a   Chu, Daniel ^a   Alder, Jeffrey D ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 7 FLUORO 9 METHYL 8 (OCTAHYDROPYRROLO[3,4 B]PYRIDIN 6 YL) 4 OXO 3 QUINOLIZINECARBOXYLIC ACID; 2 PYRIDONE DERIVATIVE; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DRUG RESISTANCE; ESCHERICHIA COLI; FEMALE; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031692749     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.10.2674     Document Type: Article

References (20)

1. Alangaden, G. J., E. K. Manavathu, S. B. Vakulenko, N. M. Zvonok, and S. A. Lerner. 1995. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39:1700-1703.
2. Alder, J., J. Clement, J. Meulbroek, N. Shipkowitz, M. Mitten, K. Jarvis, A. Oleksijew, T. Hutch, L. Paige, R. Flamm, D. Chu, and K. Tanaka. 1995. Efficacies of ABT-719 and related 2-pyridones, members of a new class of antibacterial agents, against experimental bacterial infections. Antimicrob. Agents Chemother. 39:971-975.
3. Brudney, K., and J. Dobkin. 1991. Resurgent TB in New York City. Human immunodeficiency virus, homelessness and the decline of TB programs. Am. Rev. Respir. Dis. 144:745.
4. Centers for Disease Control and Prevention. 1993. Improving adherence to antituberculosis therapy - South Carolina and New York. Morbid. Mortal. Weekly Rep. 42(4):74.
5. Centers for Disease Control and Prevention. 1993. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. Morbid. Mortal. Weekly Rep. 42(RR-7):4.
6. Clement, J., S. Tanaka, J. Alder, C. Vojtko, J. Beyer, D. Hensey, N. Ramer, D. McDaniel, and D. Chu. 1994. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone. Antimicrob. Agents Chemother. 38:1071-1078.
7. Cohn, D. L. 1995. Treatment of multidrug resistant tuberculosis. J. Hosp. Infect. 30(Suppl.):322-328.
8. Cooper, M., J. Andrews, J. Ashby, R. Matthews, and R. Wise. 1990. In vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J. Antimicrob. Chemother. 26:667-676.
9. Flamm, R., C. Vojtko, D. Chu, Q. Li, J. Beyer, D. Hensey, N. Ramer, J. Clement, and S. Tanaka. 1995. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob. Agents Chemother. 39:964-970.
10. Hardy, D., R. Swanson, D. Hensey, N. Ramer, R. Bower, C. Hansen, D. Chu, and P. Fernandez. 1987. Comparative antibacterial activities of temafloxacin hydrochloride (A-62254) and two reference fluoroquinolones. Antimicrob. Agents Chemother. 31:1768-1774.
11. Hopewell, P., M. Cynamon, J. Starke, M. Iseman, and R. O'Brien. 1992. Evaluation of new-infective drugs for the treatment and prevention of tuberculosis. Clin. Infect. Dis. 15(Suppl. 1):S282-S295.
12. Li, Q., et al. 1996. Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. J. Med. Chem. 39:3070-3088.
13. Maranetra, K. N. 1996. Treatment of multidrug resistant tuberculosis in Thailand. Chemotherapy 42(Suppl. 3):10-15.
14. McDonald, R. J., A. M. Memon, and L. B. Reichman. 1982. Successful supervised ambulatory management of TB treatment failures. Ann. Intern. Med. 96:297.
15. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Villanova, Pa.
16. Perlman, D. C., et al. 1947. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. AIDS 11(12):1473-1478.
17. Saito, H., K. Sato, H. Tomioka, and S. Dekio. 1995. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuberc. Lung Dis. 76(5):377-380.
18. Sbarbaro, J. A., and S. Johnson. 1968. TB chemotherapy for recalcitrant outpatients administered twice-weekly. Am. Rev. Respir. Dis. 97:895.
19. Sepkowitz, K. A., J. Raffalli, L. Riley, T. E. Kiehn, and D. Armstrong. 1995. Tuberculosis in the AIDS era. Clin. Microbiol. Rev. 8:180-199.
20. Yajko, M. D., J. J. Madej, M. V. Lancaster, C. A. Sanders, V. L. Cawthon, B. Gee, A. Babst, and W. K. Hadley. 1995. Colorimetric method for determining MICs of antimicrobial agents for Mycobacterium tuberculosis. J. Clin. Microbiol. 33:2324-2327.